Chest
-
Cancer Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Large cell tumor of the lung with neuroendocrine differentiation is extremely rare, accounting for only 3 % of all lung cancers. Its association with HIV/AIDs is even rarer. Typical presentation includes cough, post obstructive pneumonia, and hemoptysis. We are reporting the case of a 49 year old man with a 15 year history of HIV who was found to have an atypical presentation of a large cell tumor of the lung with neuroendocrine differentiation. ⋯ The following authors have nothing to disclose: Abhay Vakil, Hineshkumar Upadhyay, Khalid Sherani, Kelly Cervellione, Mohammed BaburyNo Product/Research Disclosure Information.
-
DVT/PE PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To analyze the characteristics of patients admitted for acute pulmonary thromboembolism (PE) and identify whether there are differences in presentation, severity and outcome at discharge of elderly patients (> 75 years) comparing to the younger patients. ⋯ The following authors have nothing to disclose: Pedro Pires Goncalves, Jacinto Hernández Borge, María del Carmen García García, Hernando Chávez Roldán, José Antonio Gutierrez Lara, María José Antona Rodríguez, Amparo Sanz Cabrera, Francisca Lourdes Márquez Pérez, Pilar Cordero Montero, Ignacio Rodríguez BlancoNo Product/Research Disclosure Information.
-
Bronchology Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: As bronchial thermoplasty (BT) gains momentum across the nation for the treatment of severe refractory asthma, logistical questions arise regarding the manufacturer guidelines for use of FEV1 in determining patient eligibility and need for hospitalization post-procedure. Currently, the recommendations are to perform BT only in patients with pre-procedure FEV1 >65% and not discharge patients who have >20% drop in FEV1 post-procedure. We present a case of BT in which these guidelines were not adhered to, and yet the patient did extremely well without complications. ⋯ We present a case in which, by FEV1 values, the patient should have never had BT performed or been directly discharged home post-procedure. Yet this patient exceeded all expectations and did extremely well. Future studies are therefore needed to define the role of FEV1 measurements in bronchial thermoplasty.Reference #1: Castro et al. AJRCCM 2010;181(2):116-24Reference #2: Pavord et al. AJRCCM 2007;176(12):1185-91Reference #3: Cox et al. NEJM 2007;356(13):1327-37DISCLOSURE: The following authors have nothing to disclose: Ching-Fei Chang, Ian Lee, Courtney Kwan, Carla SalvadorNo Product/Research Disclosure Information.
-
Transplantation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: We retrospectively reviewed the complications occurred in the immediate postoperatory (IPO) of lung transplantation (LTx). ⋯ Jordi Rello: Grant monies (from sources other than industry): Study financed partly with Spanish Government Grant FIS PI11/01122 The following authors have nothing to disclose: Jordi Riera, Berta Caralt, Salvador Augustin, Joan Ramon Masclans, Merce Canela, Antonio RomanNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The IGNITE program investigated the efficacy and safety of dual bronchodilation with once-daily QVA149 [fixed-dose combination of indacaterol (long-acting β2-agonist) and glycopyrronium (long-acting muscarinic antagonist)] for the treatment of patients with moderate-to-severe COPD. ⋯ Karen Mezzi: Employee: Novartis Employee Mark Fedele: Employee: Novartis Employee Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.